Application of Treg cell-derived exosome in preparation of drugs for preventing or treating gingival defect

By using exosomes derived from Treg cells, the problem of regeneration and repair of gingival tissue is solved, effective repair of gingival defects and anti-inflammatory and anti-infection are achieved, and the regeneration and healing of gingival tissue is promoted.

CN118948893APending Publication Date: 2024-11-15PEKING UNIV SCHOOL OF STOMATOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411049869.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively promote in-situ regeneration and repair of gingival tissue, especially in gingival defects caused by periodontal diseases and trauma. Traditional treatments are complex and cannot achieve true in-situ regeneration.

Method used

Treg cell-derived exosomes are used as drugs to prepare for prevention or treatment of gingival defects, and accelerate gingival wound healing by promoting soft tissue regeneration, angiogenesis, anti-inflammatory and anti-infective effects.

Benefits of technology

Treg cell-derived exosomes play an effective role in the healing of gingival inflammation wounds, promote gingival defect repair, reduce secondary damage and inflammatory cascades, and improve the regeneration and repair efficiency of gingival tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948893A_ABST
    Figure CN118948893A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, in particular to application of a Treg cell-derived exosome in preparation of a medicament for preventing or treating gingival defect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to the use of Treg cell-derived exosomes as a drug for preparing a drug for preventing or treating gingival defects. Background Art

[0002] Periodontal disease is a common problem worldwide. It is an inflammation of the periodontal tissue caused by a variety of pathogenic factors, often accompanied by the loss of soft and hard tissues supporting the teeth. [1][2] . The realization of periodontal regeneration poses a substantial challenge to dental aesthetics and periodontal disease repair. At present, the main methods for treating gingival defects in clinical practice are non-surgical and surgical treatments. Non-surgical treatment is to remove the cause of local irritation, while surgery is mainly based on autologous soft tissue transplantation, which is complex and traumatic, with limited restoration of appearance and unable to achieve true in situ regeneration. Therefore, research on in situ regeneration and repair of gingival soft tissue is extremely urgent.

[0003] The gingiva is part of the oral soft tissue, and its main function is to protect teeth and support periodontal structures. The gingival regeneration process aims to restore the integrity and function of the epidermis. To this end, multiple tissue-resident cells and recruited immune cells work together to effectively repair injured tissue. [3] This coordinated interaction in time and space requires strict regulation to prevent additional damage such as excessive immune response and excessive inflammation. The gingival repair process involves the regeneration of soft tissue, angiogenesis, and the restoration of anti-inflammatory and anti-infection capabilities. Gingival tissue is exposed to the oral environment and is susceptible to bacterial infection. The repair process needs to take into account both anti-inflammatory and antibacterial properties.

[0004] Recent studies have shown that adaptive immunity, including T cells, plays a central role. Regulatory T cells (Tregs) have an indirect role in regulating injury-induced inflammation. Excessive inflammation after tissue injury can lead to defective tissue healing and remodeling. Treg cells from various tissues are recruited to the site of injury to promote inflammation resolution and control immunity. They can indirectly regulate regeneration by regulating neutrophils, stimulating macrophage polarization, and controlling helper T cells. [4] In addition, Treg cells can directly support regeneration by stimulating local progenitor cells [5] .

[0005] As an effective means of intercellular communication, exosomes play an important role in regulating the immune microenvironment. Studies have shown that Treg cells secrete exosomes with more membrane molecules, such as CD25, CTLA4, and CD73. In a mouse arthritis model, Treg cell-derived exosomes preferentially aggregate in the inflammatory area and improve the imbalance of Th17 / Treg cells in arthritis mice. [6] .

[0006] However, it is still unclear whether Treg cell-derived exosomes can become a new strategy to regulate the immune microenvironment of periodontal tissues. The healing model of gingival tissue still needs further exploration and improvement. It is necessary to find key pathways for regulating the immune microenvironment of periodontal tissues to provide new ideas for tissue engineering technology to promote the repair and regeneration of gingival tissue defects. Summary of the invention

[0007] Existing studies have also shown that Treg cells are key regulators of inflammation, including thymic Treg cells and peripheral Treg cells, which are essential for immune tolerance and homeostasis. Foxp3 gene is a major regulator in the development of Treg cells [7] The protective role of Treg cells in many diseases has been established. Some scholars have found that osteopontin derived from Treg cells can promote microglia-mediated white matter repair after ischemic stroke, and increasing the abundance of endogenous Treg cells 1-7 days after ischemic injury can have a protective effect on the brain. [8] Foxp3+Tregs may play a role in the inflammatory microenvironment by mediating the secretion of inflammatory cytokines and promoting the anti-inflammatory phenotype of immune cells. The secretion of anti-inflammatory cytokines such as IL-10 can further enhance the balance of pro-inflammatory phenotype dominance in lesions. In addition, the reversal from a pro-inflammatory environment to an anti-inflammatory environment can improve tissue repair, reduce secondary injury cells, and control the inflammatory cascade and spread. [9] .

[0008] Exosomes are extracellular vesicles with an average diameter of about 100 nm that can be taken up by distant cells, affecting their behavior and function and serving as a means of intercellular communication.

[10] Exosomes contain a variety of cellular components, including DNA, RNA, lipids, metabolites, and cytoplasmic and cell surface proteins. Studies have shown that exosomes derived from mesenchymal stem cells can accelerate gingival wound healing through IL-1RA secretion.

[11] However, whether Treg cell-derived exosomes can promote gingival damage repair has not been demonstrated, which prompted us to conduct further studies.

[0009] The present invention found that exosomes derived from Treg cells play an effective role in promoting the healing of gingival inflammation wounds, providing a new idea for promoting the repair of gingival defects by combining Treg cells with exosomes.

[0010] Specifically, the present invention provides the use of exosomes derived from Treg cells as a drug for preparing a drug for preventing or treating gingival defects.

[0011] In some embodiments, the gingival defect comprises a gingival defect caused by periodontal disease and / or trauma.

[0012] In some embodiments, the periodontal disease includes gingivitis and periodontitis, and the trauma includes trauma caused by external factors and trauma caused by surgical procedures.

[0013] In some embodiments, the Treg cell-derived exosomes have the functions of: (a) promoting the repair of gingival defects;

[0014] and / or (b) anti-inflammatory and anti-infective effects.

[0015] In some embodiments, the repair comprises promoting regeneration and angiogenesis of soft tissue.

[0016] In some embodiments, the Treg cell-derived exosomes are anti-Gram-negative bacteria.

[0017] In some embodiments, the Treg cell-derived exosomes upregulate the expression of Foxp3.

[0018] In some embodiments, the medicament further comprises Treg cells.

[0019] In some embodiments, the drug further comprises a pharmaceutically acceptable carrier or excipient.

[0020] In some embodiments, the drug is in the form of an injection, a spray, or a dressing.

[0021] Compared with the prior art, the present invention has the following advantages:

[0022] (1) The present invention finds that exosomes derived from Treg cells play an effective role in promoting wound healing in gingival inflammation, and therefore can be used as a drug for preventing or treating gingival defects.

[0023] (2) The present invention also found that Treg cells play an important role in gingival defects, and therefore exosomes derived from Treg cells can be used in combination to prevent or treat gingival defects.

[0024] (3) The gingival defects in the present invention include gingival defects caused by periodontal disease and / or trauma, especially gingival defects caused by periodontal disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments according to the present invention and should not be regarded as limiting the scope of the present invention.

[0026] Figure 1 The picture and bar graph of gum wound repair provided in Example 1 of the present invention;

[0027] Figure 2 The slice diagram provided in Example 1 of the present invention, wherein the scales in the first row of pictures all represent 500 μm, and the scales in the second row of pictures all represent 100 μm;

[0028] Figure 3 Pictures and bar graphs showing the repair conditions of different groups of gingival defects provided in Example 2 of the present invention;

[0029] Figure 4 This is a slice diagram provided in Example 2 of the present invention, wherein the scale in the diagram represents 50 μm;

[0030] Figure 5 This is a fluorescence analysis diagram provided in Example 2 of the present invention, wherein Foxp3 positive area refers to the Foxp3 positive area, and the scale in the picture represents 50 μm. DETAILED DESCRIPTION

[0031] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms and experimental procedures related to protein, nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology, molecular detection, computer, etc. used herein are the terms and conventional procedures widely used in the corresponding fields.

[0032] The contents of the present invention will be described in detail below.

[0033] The gums are part of the oral soft tissues, and their main function is to protect teeth and support periodontal structures. Common causes of gum defects include periodontal disease, trauma, and other factors. Gingivitis and periodontitis are common periodontal diseases and are also common causes of gum defects. Trauma includes trauma caused by external factors such as mechanical damage and trauma caused by surgical procedures.

[0034] If there is a gingival defect, the gingival tissue is exposed to the oral environment and is susceptible to bacterial infection. The repair process needs to take into account both anti-inflammatory and antibacterial effects. Therefore, its repair process is more complicated than other tissue repairs, involving soft tissue regeneration, angiogenesis, and the restoration of anti-inflammatory and anti-infection capabilities.

[0035] Although regulatory T cell-derived exosomes play a role in the regeneration of different tissues, due to the different structures, functions and pathophysiological environments of each tissue, research on gingival defect repair needs to consider its unique oral environment and soft tissue characteristics, which is significantly different from the repair of cornea, tendon and pancreatic islet. This is also the significance of further research in this invention.

[0036] The present invention firstly specifically eliminates the gingival defect of mice expressing Treg cells of Foxp3 as a model, and verifies that Treg cells play an important role in gingival defect.

[0037] For the oral cavity, bacterial infection triggers inflammation, leading to destruction and atrophy of gingival tissue. Gram-negative bacteria are common bacteria in clinical oral cavity. Therefore, further, the present invention uses LPS, a cell wall component of Gram-negative bacteria, to simulate the inflammatory environment, and verifies that Treg cell-derived exosomes have immunomodulatory and anti-inflammatory effects, which can reduce inflammatory responses and promote tissue repair. Therefore, due to the inflammation and tissue destruction caused by periodontal disease, supplementing Treg exosomes can help control inflammation and promote gingival tissue regeneration. Acute injuries caused by trauma and surgery, due to exposure to the oral environment, the anti-inflammatory and tissue repair-promoting effects of Treg-derived exosomes are helpful to accelerate healing.

[0038] Based on the above content, the present invention provides the use of exosomes derived from Treg cells as a drug for preparing a drug for preventing or treating gingival defects.

[0039] For example, in some embodiments, exosomes derived from Treg cells are used to prepare drugs for preventing or treating gum defects caused by periodontal disease. In some embodiments, exosomes derived from Treg cells are used to prepare drugs for preventing or treating gum defects caused by acute injuries caused by trauma and surgery.

[0040] In the present invention, prevention refers to preventing the occurrence of gingival defects or delaying their occurrence; treatment refers to curing, healing, alleviating, relieving, changing, remedying, improving or ameliorating the symptoms of gingival defects.

[0041] In the present invention, exosomes derived from Treg cells can be prepared or purchased commercially. For example, exosomes derived from Treg cells can be prepared by the method shown in Example 1 of CN114569792B, or by the method shown in prior art document 4 involved in this application.

[0042] The Treg cell-derived exosomes provided by the present invention can be used to prevent or treat gingival defects, such as gingival defects caused by periodontal disease and / or trauma.

[0043] An effective preventive amount or an effective therapeutic amount of Treg cell-derived exosomes is administered to the subject.

[0044] Subjects include mammals and non-mammals, including humans, primates such as monkeys, chimpanzees, orangutans and gorillas, cats, dogs, rabbits, cows, horses, goats, sheep and pigs, and rodents such as mice, rats, hamsters and guinea pigs.

[0045] Furthermore, the Treg cell-derived exosomes have the functions of: (a) promoting the repair of gingival defects;

[0046] and / or (b) anti-inflammatory and anti-infective effects. Wherein, the repair includes promoting the regeneration and angiogenesis of soft tissue.

[0047] In some embodiments, exosomes derived from Treg cells are used to prepare anti-inflammatory and anti-infective drugs, such as anti-Gram-negative bacteria drugs. In some embodiments, exosomes derived from Treg cells are used to prepare gingival defect repair drugs.

[0048] As described above, the present invention verifies that exosomes derived from Treg cells have anti-Gram-negative bacteria effects.

[0049] Foxp3 (forkheadbox Protein 3) is the main transcription factor that regulates the T cell (Treg) lineage. Foxp3 plays an important role in the development of Treg cells and immune regulation. The loss of Foxp3 in Treg cells will cause Treg cells to acquire pro-inflammatory properties, thereby aggravating the progression of autoimmune diseases or significantly improving the immunosuppressive effect. The present invention has found that exosomes derived from Treg cells also have the effect of enhancing the expression of Foxp3 in gingival defect repair, thereby achieving anti-inflammatory and anti-infection while achieving the effect of gingival defect repair.

[0050] As described above, the present invention finds that Treg cells play an important role in the repair of gingival defects. Therefore, in some embodiments, the drug also includes Treg cells. That is, the drug in the present invention can not only contain exosomes derived from Treg cells as an active ingredient, but also include Treg cells as an active ingredient. Therefore, Treg cells can also be used as a drug for preparing a gingival defect.

[0051] In some embodiments, the drug further comprises a pharmaceutically acceptable carrier or excipient.

[0052] Pharmaceutically acceptable carriers or excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopheryl polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms (such as Tween or other similar polymer delivery matrices), serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins (including 2- and 3-hydroxypropyl-β-cyclodextrin), or other soluble derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

[0053] In some embodiments, the drug is in the form of an injection, a spray, or a dressing.

[0054] The injection can be a liquid injection such as an oil solution, water or oil suspension, emulsion, etc., powder for injection, tablet for injection; the spray can be a water mist spray, emulsion spray, etc. The dressing contains effective active ingredients, and the dressing can be a calcium alginate dressing, silver dressing, foam dressing, hydrocolloid dressing and hydrogel dressing, etc.

[0055] To facilitate understanding of the technical solutions of the embodiments of the present invention, the following describes the related technologies of the embodiments of the present invention. The following related technologies can be combined with the technical solutions of the embodiments of the present invention as optional solutions, and they all belong to the protection scope of the embodiments of the present invention.

[0056] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0057] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0058] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0059] Unless otherwise specified, “M” in this article refers to “mol / L”, “n M” refers to “n mol / L”, “μM” refers to “μmol / L” and “mM” refers to “m mol / L”.

[0060] Example 1

[0061] Foxp3 DTR Mice and C57 / B6J mice were intraperitoneally injected with diphtheria toxin, respectively, at a dose of 0.05 mg / kg based on the weight of the mice, to obtain the induced knockout Foxp3 gene knockout group, i.e., the Treg cell elimination group (experimental group) and the control group, and then a full-thickness gingival defect model with a diameter of 2 mm was established, and the gingival damage was the gingival tissue of the hard palate. There were 5 mouse model samples in each group. The degree of repair of gingival damage in mice with different gingival defect models was observed 5 and 7 days after the injury. The degree of repair was quantitatively analyzed for wound size using ImageJ.

[0062] Figure 1 The figure shows pictures of the defect on different days and a bar chart showing the statistical data of the repair status. Figure 1 It can be seen that on the 5th day after injury, the size of the defect in the experimental group increased from 3.14 mm to 2 Reduced to about 1.8mm 2 , while the size of the defect in the control group ranged from 3.14mm 2 Reduced to about 0.5mm 2 On the 7th day after injury, the size of the defect in the experimental group was reduced from 3.14 mm 2 Reduced to about 1.6mm 2 , while the size of the defect in the control group ranged from 3.14mm 2 Reduced to about 0.5mm 2 Therefore, it can be concluded that after specific knockout of the Foxp3 gene or specific elimination of Treg cells, the gingival wound regeneration ability of mice was significantly slower than that of the control group.

[0063] In this example, tissue samples were collected on the 5th day after injury, and HE staining of different tissue samples was performed for histological evaluation of wound healing. The results are shown in Figure 2 .from Figure 2 It can be seen that the ablation of Treg cells in the experimental group hindered the healing of gingival lesions in mice.

[0064] Example 2

[0065] A full-thickness gingival injury model with a diameter of 2 mm was constructed for C57 / B6J mice. The constructed gingival injury models were divided into four groups and treated as follows: control group, LPS injection group, LPS+Treg exosome (abbreviated as EXO) injection group, and LPS+CD4+T cell exosome injection group, with 5 model mice in each group; the control group was injected with 20 μl of PBS; the LPS injection group was injected with 20 μl of LPS solution (the solvent was PBS, Sigma L2880), and the LPS The concentration of S was 1mg / ml; the LPS+Treg exosome injection group was injected with 20μl of a mixture containing LPS and Treg exosomes, the solvent was PBS, in which the concentration of LPS was 1mg / ml and the Treg exosomes were 20μg; the LPS+CD4+T cell exosome injection group was injected with 20μl of a mixture containing LPS and CD4+T cell exosomes, the solvent was PBS, in which the concentration of LPS was 1mg / ml and the CD4+T cell exosomes were 20μg. The injection sites were all around the wound. The injections were respectively made on the second day of the injury, and the injury healing was observed on the 3rd, 5th, and 7th days after the injury.

[0066] We found that compared with the LPS injection group, the LPS+Treg exosome injection group could accelerate the healing of gingival wounds, while the LPS+CD4+T cell exosome injection group showed no significant changes, indicating that CD4+T cell exosomes could not accelerate the healing of gingival wounds, while Treg exosomes could accelerate the healing of gingival wounds ( Figure 3 and Figure 4 ).

[0067] At the same time, immunofluorescence analysis was performed on different samples on the 7th day using Foxp3 antibody, and it was found that the expression of Foxp3 fluorescence signal in the LPS+Treg exosome injection group was significantly higher than that in other groups ( Figure 5 ).

[0068] The present invention illustrates the method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned steps, that is, it does not mean that the present invention must rely on the above-mentioned steps to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0069] References

[0070] [1]Hajishengallis G,Chavakis T.Local and systemic mechanisms linkingperiodontal disease and inflammatory comorbidities[J].Nature ReviewsImmunology,2021,21(7):426-440.

[0071] [2] Wang Xing. The Fourth National Oral Health Epidemiological Survey Report[J]. People's Medical Publishing House, 2018.

[0072] [3]Caetano AJ,Yianni V,Volponi A,et al.Defining human mesenchymal and epithelial heterogeneity in response to oral inflammatory disease[J].eLife,2021,10:e62810.

[0073] [4]Sakaguchi S, Mikami N, Wing JB, et al. Regulatory T Cells and HumanDisease[J]. Annual Review of Immunology, 2020, 38(1):541-566.

[0074] [5]Ali N, Zirak B, Rodriguez RS, et al. Regulatory T Cells in SkinFacilitate Epithelial Stem Cell Differentiation[J]. Cell, 2017, 169(6):1119-1129.e11.

[0075] [6]Chen J,Huang F,Hou Y,et al.TGF-β-induced CD4+FoxP3+regulatory Tcell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model[J].Cellular&Molecular Immunology,2021,18(11):2516-2529.

[0076] [7]Lisa G,Clemens S,Michael B.Treg cells in autoimmunity:fromidentification to Treg-based therapies[J]Seminars Immunopathol.2019;41(3):301–314.

[0077] [8]Ligen S,Zeyu S,Wei S,et al.Treg cell-derived osteopontin promotesmicroglia-mediated white matter repair after ischemic stroke[J]Immunity.2021;54(7):1527–1542.e1528.

[0078] [9]Li C,Xiong W,Wan B,et al.Role of peripheral immune cells in spinalcord injury.Cell Mol Life Sci.2022Dec 7;80(1):2.

[0079]

[10] Pegtel DM,Gould SJ.Exosomes[J]Ann Rev Biochem.2019;88(1):487–514.doi:10.1146 / annurev-biochem-013118-111902.

[0080]

[11] Kou X,Shi S,et al.The Fas / Fap-1 / Cav-1complex regulates IL-1RAsecretion in mesenchymal stem cells to accelerate wound healing.Sci TranslMed.2018 Mar 14;10(432):eaai8524.

Claims

1. Application of Treg cell-derived exosomes as drugs for the prevention or treatment of gingival defects.

2. The use according to claim 1, characterized in that: The gum defects include gum defects caused by periodontal disease and / or trauma.

3. The use according to claim 2, characterized in that: The periodontal diseases include gingivitis and periodontitis, and the trauma includes trauma caused by external factors and trauma caused by surgical procedures.

4. The use according to claim 1, characterized in that: The Treg cell-derived exosomes have the functions of: (a) promoting the repair of gingival defects; and / or (b) anti-inflammatory and anti-infective effects.

5. The use according to claim 4, characterized in that: The repair includes promoting regeneration and angiogenesis of soft tissue.

6. The use according to claim 4, characterized in that: The Treg cell-derived exosomes are resistant to Gram-negative bacteria.

7. The use according to claim 4, characterized in that: The Treg cell-derived exosomes upregulate the expression of Foxp3.

8. The use according to any one of claims 1 to 7, characterized in that: The drug also includes Treg cells.

9. The use according to claim 8, characterized in that: The medicine also includes a pharmaceutically acceptable carrier or excipient.

10. The use according to claim 9, characterized in that: The medicine is in the form of injection, spray or dressing.